

GAU 1635

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRADEMARK OFFICE
2000

Application of: Schneider
Serial No.: 09/435,249
Filing Date: November 5, 1999
For: **Treatment of Parkinson's Disease
With Oligonucleotides**
Docket No. SCH01.NP001

Art Unit: 1635
Examiner: Schmidt, M.

P#3
RECEIVED

OCT 11 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 28, 2000.

By:



Heather S. Richman

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the references, listed on Form PTO-1449 (PTO-2), in accordance with 37 CFR 1.98(a)(2).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1) **This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.

- ☐ **before** the mailing date of a first Office Action on the merits.
- ☒ **after** the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:
- RECEIVED
OCT 1 2000
TECH CENTER 1600/2900

☐ the Statement under 37 CFR 1.97(e) (see "Statement" below);

or

☒ the Fee of \$240.00 set forth in 37 CFR 1.17(p); or

☐ No fee is owed by the applicants.

- ☐ **after** the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Supplemental Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

(If this box is checked, do not check any further Statement boxes.)

or

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

The person making the statement is:

- ☐ the inventor(s) who sign(s) below:

Signature of the Inventor(s)

Typed or Printed Name of the Inventor(s)

or

- ☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

Signature of the Person(s)

Typed or Printed Name of the Person

Address of Person Signing

or

- ☐ the undersigned attorney who signs on the basis of the information:
- ☐ supplied by the inventor(s).
 - ☐ supplied by an individual designated in 37 CFR 1.56(c).
 - ☐ in the attorney's file.

Signature of the Attorney

(3) **Petition**

- ☐ Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Supplemental Information Disclosure Statement and on the enclosed Form PTO-1449, in the examination of the above-identified patent application.

(4) **Fees**

- ☐ **No Fee** is owed by the applicants.
- ☒ **The IDS Fee** of \$240.00 under 37 CFR 1.17(p) is enclosed herewith.
- ☐ **The Petition Fee** of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(5) **Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$_____.
- ☒ Charge Account No. 50-0491 in the amount of \$240.00. (A duplicate of this request is attached).

(6) **Authorization to Charge Additional Fees**


- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 50-0491.

(7) **Instructions as to Overpayment**

- ☒ Please credit Account No. 50-0491 for any overpayment.
- ☐ Please refund Thomas Jefferson University in the amount of \$_____.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Clifford K. Weber
Registration No. 42,215
Attorney for Applicant
THOMAS JEFFERSON UNIVERSITY
1020 Walnut Street – Suite 620
Philadelphia, PA 19107-5587
Tel: (215) 503-0757
Fax: (215) 923-3613

Date: 9/28/2000